Nosopharm obtains US patent for NOSO-502, a first-in-class novel antibiotic

Nosopharm obtains US patent for NOSO-502, a first-in-class novel antibiotic   Patent secures US market exclusivity for Nosopharm and covers numerous chemical analogs, reinforcing protection of NOSO-502’s chemical space   Lyon, France, April 22, 2020 – Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces it has been granted a US patent for NOSO-502. NOSO-502 is Nosopharm...

READ MORE...

Medicen Paris Region appoints Jessica Leygues as CEO

Medicen Paris Region appoints Jessica Leygues as CEO With many years of valuable experience, Jessica Leygues will launch concrete reindustrialization initiatives to accelerate growth in the French healthcare industry and boost national sovereignty in order to recover from the COVID-19 pandemic   Paris, France, April 20, 2020 - Medicen Paris Region, Europe's leading health cluster, today announces the appointment of Jessica Leygues as CEO, with approval from the board of dire...

READ MORE...

Yposkesi’s clinical batches of G1XCGD lentiviral vector used in rare immune system disease study 

International research team published initial clinical trial results in Nature Medicine of nine X-Linked Chronic Granulomatous Disease (CGD) patients    Corbeil-Essonnes, France, January 29, 2019 – Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production, today announces it produced the lentiviral vectors used in the gene therapy clinical trial in patients severely affec...

READ MORE...

Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPAR gamma agonist Second Orphan Drug Designation granted by the FDA for leriglitazone in addition to X-linked adrenoleukodystrophy (X-ALD) Potential for seven years of marketing exclusivity in the USA upon approval in the orphan designation indication Mataró, Barcelona, Spain and Charleroi, Belgium, October 17, 2019 – Minoryx Therapeutics, a company that specializes in the...

READ MORE...

Medicen Paris Region reorganizes its Strategic Areas of Activities (DAS) to bring engineers and doct

Medicen Paris Region reorganizes its Strategic Areas of Activities (DAS) to bring engineers and doctors closer together New DAS organization within cluster reflects changes in health ecosystem and integrates techno-therapies Paris, France, October 10, 2019 – Medicen Paris Region, Europe’s leading health competitiveness cluster, today announces a reorganization of its Strategic Activities Areas (Domaines d’Activité Stratégiques - DAS), and its governanc...

READ MORE...

Innovative Solution Providers’ symposium focused on immunotherapies

News report – Innovative Solution Providers’ symposium focused on immunotherapies   On September 30, 2019, 100 scientific professionals gathered in Paris for the 1st edition of a unique symposium to discuss ‘Innovative & Integrated Solution Providers in Translational Research to Develop Immunotherapies – Toward Next Generation of Solution Providers’.   Exploring the current trends in immunotherapies discovery &a...

READ MORE...

Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreichâ€

Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule  Mataró, Barcelona, Spain and Charleroi, Belgium, October 8, 2019 – Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan central nervous system (CNS) diseases, today announces that it has completed recruitment in the FRAMES phase 2 clinical trial of its novel PPARγ agonist, leriglitazone (MIN-102), in patients with Friedreich&...

READ MORE...

Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer In

Less than one year after signing agreement, the GPCR expert has reached key discovery milestones in two independent projects   Strasbourg, France, September 30, 2019 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors in neurology, oncology and rare diseases, today announces the achievement of two discovery milestones in its multi-target collaborati...

READ MORE...

Domain Therapeutics invests in Ermium Therapeutics to develop first-in-class CXCR4 candidate for a

G Protein Coupled Receptor (GPCR) expert will invest up to €3M ($3.3M) to unlock the therapeutic potential of breakthrough asset   Strasbourg, France, September 11, 2019 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors in neurology, oncology and rare diseases, today announces its investment of up to €3M ($3.3M) in Ermium Therapeutics.   Founded in June 2...

READ MORE...

Keranova raises €24M in second round of financing

Funds will enable company to finalize regulatory process with view to obtaining CE mark for ultra-fast robotized ophthalmology laser   Saint-Etienne and Lyon, France, September 10, 2019 – Keranova, a company specializing in the development of surgical ophthalmology equipment, today announces that it has raised €24M ($26.5M) in a second round of financing, prompted by its long-standing shareholders Mérieux Equity Partners and Supernova Invest. Financière Arbev...

READ MORE...